Barbara Ann Karmanos Cancer Institute
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
Inclusion Criteria: * Participant must have histologically or cytologically confirmed metastatic colorectal adenocarcinoma. There must be previous documentation of RAS (Rat sarcoma mutation), BRAF (B-Raf proto-oncogene, Serine/threonine kinase), MSI/MMR (microsatellite instability, mismatch repair) , and HER2 (Human epidermal growth factor receptor 2) status. * Participant must have progressed on or been intolerant to the following previous treatments (if not contraindicated): * Fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy * Anti-VEGF (vascular endothelial growth fac…
Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class
TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device